PHILIPPE BIERLING, M.D.; GEORGES KARIANAKIS, M.D.; NAJIB DUEDARI, M.D.; CHRISTIAN DESAINT, M.D.; ERIC OKSENHENDLER, M.D.; BAHMAN HABIBI, M.D.; YVES BROSSARD, M.D.
To the editor: Treatment with intravenous anti-D (rhesus) immunoglobulins has been reported to be effective and safe in patients with immune thrombocytopenia (1). The mechanism of this treatment remains controversial (1, 2). Due to the risk of using corticosteroids in carriers of the human immunodeficiency virus (HIV) (3, 4), a therapeutic trial using immunoglobulins for various rhesus antigens has been done in HIV carriers with immune thrombocytopenia and bleeding. We report the treatment results in two patients, showing that the platelet increment requires the interaction between erythrocyte antigens and their specific antibodies.
A 27-year-old homosexual man (body weight, 65 kg)
BIERLING P, KARIANAKIS G, DUEDARI N, DESAINT C, OKSENHENDLER E, HABIBI B, et al. Anti-Rhesus Antibodies, Immune Thrombocytopenia, and Human Immunodeficiency Virus Infection. Ann Intern Med. ;106:773–774. doi: 10.7326/0003-4819-106-5-773_3
Download citation file:
Published: Ann Intern Med. 1987;106(5):773-774.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use